All stocks / RVPH
REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH
Reviva Pharmaceuticals Holdings (RVPH): no warning signs from our rules in the last 12 months and the latest annual figures in plain language. Each fact links to its SEC filing.
Market listing
- Full name
- REVIVA PHARMACEUTICALS HOLDINGS INC
- Market tier
- OTCQB
- Trading status
- Active
- Last trade
- 09:35:27
News headlines
The financial report, and what it means
Annual figures to 2025-12-31- Net loss
- ($19,864,902)
It spends more than it earns
Under strainThe company lost $19.9 million in the year. It reported no sales.
- Cash and cash equivalents
- $14,438,792
- Net cash used in operating activities
- ($24,594,643)
The cash could run out soon
Under strainIt had $14.4 million in the bank and used about $2 million a month. At that pace the money lasts about 7 months unless it borrows or sells more shares.
- Total assets
- $15,923,198
- Total liabilities
- $7,275,553
It owns more than it owes
SteadyEverything the company owns adds up to $15.9 million. Its debts and unpaid bills add up to $7.3 million. That is about $0.46 owed for every $1 owned.
What this adds up to
2 of 3 checks show strain. It spends more than it earns. The cash could run out soon. These are facts from the company's own reports, not a recommendation.
Signals
Estimated float about 13,110,377 shares as of 2026-11-10: 13,110,377 outstanding minus 0 held by 0 reporting insider(s).
Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record
Shares outstanding
Source: SEC filingsPrice chart
Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets
Recent filings
| 2026-11-13 | 8-K | FORM 8-K |
| 2026-11-13 | 10-Q | FORM 10-Q |
| 2026-11-09 | DEF 14A | FORM DEF 14A |
| 2026-11-09 | ARS | FORM ARS |
| 2026-10-29 | PRE 14A | FORM PRE 14A |
| 2026-08-13 | SCHEDULE 13G/A | |
| 2026-08-12 | 8-K | FORM 8-K |
| 2026-08-12 | 10-Q | FORM 10-Q |
| 2026-08-03 | SCHEDULE 13G/A | |
| 2026-07-31 | SCHEDULE 13G/A | |
| 2026-07-10 | 25-NSE | |
| 2026-05-15 | SCHEDULE 13G/A |
Common questions about RVPH
Does RVPH file reports with the SEC?
Yes. Reviva Pharmaceuticals Holdings files with the SEC under company number 0001742927. The most recent filing we hold is a 8-K dated 2026-11-13.
Source recordHow many RVPH shares are outstanding?
13,110,377 shares as of 2026-11-10, as reported to the SEC.
Source recordHas RVPH filed reports late?
We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.
Who runs Reviva Pharmaceuticals Holdings?
Officers named in its insider filings: Laxminarayan Bhat (President and CEO) and Narayan Prabhu (Chief Financial Officer).
Source recordIs Reviva Pharmaceuticals Holdings making money?
The company lost $19.9 million in the year. It reported no sales. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)
Source record